Patents by Inventor R. Blake Pepinsky

R. Blake Pepinsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200317775
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: February 13, 2020
    Publication date: October 8, 2020
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20200297800
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.
    Type: Application
    Filed: February 5, 2020
    Publication date: September 24, 2020
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, John McCoy
  • Publication number: 20200270335
    Abstract: Proteins containing a DKK2 polypeptide or a fragment or variant thereof are described. These proteins contain human serum albumin sequences and/or include substitutions in the DKK2 polypeptide that decrease heparin binding. These proteins are useful in the treatment of disorders such as acute kidney injury and fibrosis.
    Type: Application
    Filed: December 16, 2016
    Publication date: August 27, 2020
    Inventors: R. Blake Pepinsky, Richelle Sopko, Joshua Mugford, Andreas Lehmann, Joseph W. Arndt, Nels E. Pederson, Brenda K. Minesinger
  • Publication number: 20200031895
    Abstract: Methods of activating GDF11 proteins in vitro as well as formulations of mature GDF11 polypeptides with enhanced solubility at neutral pH are provided.
    Type: Application
    Filed: December 15, 2017
    Publication date: January 30, 2020
    Inventors: R. Blake Pepinsky, Andreas Lehmann, Dingyi Wen
  • Publication number: 20190359706
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist.
    Type: Application
    Filed: April 23, 2019
    Publication date: November 28, 2019
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky
  • Patent number: 10308706
    Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: June 4, 2019
    Assignee: Biogen MA Inc.
    Inventors: David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas
  • Publication number: 20190161546
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: June 26, 2018
    Publication date: May 30, 2019
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20190060398
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.
    Type: Application
    Filed: March 12, 2018
    Publication date: February 28, 2019
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, John McCoy
  • Publication number: 20180111994
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist.
    Type: Application
    Filed: September 15, 2017
    Publication date: April 26, 2018
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky
  • Patent number: 9796780
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist. An exemplary method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a composition comprising a LINGO-2 antagonist selected from the group consisting of: (i) a soluble LINGO-2 polypeptide; (ii) a LINGO-2 antibody or antigen-binding fragment thereof; (iii) a LINGO-2 antagonist polynucleotide; (iv) a LINGO-2 aptamer; and (v) a combination of two or more of said LINGO-2 antagonists.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: October 24, 2017
    Assignee: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky
  • Patent number: 9745375
    Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 29, 2017
    Assignee: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Christilyn Graff
  • Publication number: 20170037126
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: July 20, 2016
    Publication date: February 9, 2017
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20160368984
    Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 22, 2016
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Christilyn Graff
  • Publication number: 20160213745
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.
    Type: Application
    Filed: December 22, 2015
    Publication date: July 28, 2016
    Inventors: Sha Mi, R. Blake Pepinsky, John McCoy
  • Publication number: 20160159878
    Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 9, 2016
    Inventors: Daniel H.S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
  • Publication number: 20160083468
    Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.
    Type: Application
    Filed: June 25, 2015
    Publication date: March 24, 2016
    Inventors: Sha Mi, R. Blake Pepinsky, Christilyn Graff
  • Publication number: 20160002329
    Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. Additional methods include methods for inhibiting the binding of the Sp35 polypeptide with the ErbB2 polypeptide and a method for increasing ErbB2 phosphorylation by contacting oligodendrocytes with an effective amount of a composition comprising an Sp35 antagonist of the invention. Further embodiments of the invention include methods of inhibiting the binding of the Sp35 polypeptide with the ErbB2, increasing ErbB2 phosphorylation and promoting oligodendrocyte differentiation comprising contacting oligodendrocyte or oligodendrocyte progenitor cells with an ErbB2 binding agent.
    Type: Application
    Filed: June 9, 2015
    Publication date: January 7, 2016
    Inventors: Sha Mi, R. Blake Pepinsky, John McCoy
  • Patent number: 9228015
    Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: January 5, 2016
    Assignee: Biogen Idec MA Inc.
    Inventors: Daniel H. S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
  • Publication number: 20150315273
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: April 2, 2015
    Publication date: November 5, 2015
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20150274808
    Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
    Type: Application
    Filed: March 4, 2015
    Publication date: October 1, 2015
    Inventors: David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas